Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment.
The soluble Interleukin-2 Receptor (sIL-2R) serum levels were assessed in 42 patients with Hairy-Cell Leukemia (HCL) at diagnosis and after alpha-Interferon therapy and correlated with spleen size, peripheral hematological values, hairy cell index (HCI) and clinical response. Serum sIL-2R levels were significantly increased in all HCL patients, particularly in those with a higher HCI (> 0.50) and in non-splenectomized patients. Among the 26 HCL patients who were studied before and after 12 months of alpha-IFN treatment, 16 normalized the sIL-2R level and 10 did not. Our findings suggest that sIL-2R levels in HCL patients correlate with the splenic and bone marrow tumor burden as assessed by HCI. In addition patients with low levels of sIL-2R at diagnosis appear to have a better chance of achieving a good clinical response.
Lauria
F
F
Istituto di Ematologia L. e A. Seràgnoli, Università di Bologna, Italy.
Rondelli
D
D
Raspadori
D
D
Zinzani
P L
PL
Benfenati
D
D
Pileri
S
S
Sabattini
E
E
Tura
S
S
D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000097:blood* / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D007958:Leukocyte Count; D008297:Male; D009504:Neutrophils / Q000473:pathology; D010976:Platelet Count; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D013154:Spleen / Q000473:pathology
D014408:Biomarkers, Tumor; D006454:Hemoglobins; D016898:Interferon-alpha; D015375:Receptors, Interleukin-2